Literature DB >> 15749856

Protein conformation significantly influences immune responses to prion protein.

Azadeh Khalili-Shirazi1, Sonia Quaratino, Marco Londei, Linda Summers, Mourad Tayebi, Anthony R Clarke, Simon H Hawke, Graham S Jackson, John Collinge.   

Abstract

In prion diseases, such as variant Creutzfeldt-Jakob disease normal cellular prion protein (PrPC), a largely alpha-helical structure is converted to an abnormal conformational isoform (PrPSc) that shows an increase in beta-sheet content. Similarly, the recombinant form of PrPC (ralpha-PrP) can be converted to a conformation dominated by beta-sheet (rbeta-PrP) by reduction and mild acidification in vitro, a process that may mimic in vivo conversion following PrPC internalization during recycling. Despite PrPSc accumulation and prion propagation in the lymphoreticular system before detectable neuroinvasion, no Ab response to PrP has been detected, probably due to immune tolerance. To investigate how the immune system may respond to alpha- and beta-PrP, we immunized Prnp(0/0) mice that are not tolerant of PrP with ralpha-PrP and rbeta-PrP. In this study, we show that although T cells stimulated by these differently folded conformers PrP recognize similar immunodominant epitopes (residues 111-130 and 191-210) the cytokine profile in response to ralpha- and rbeta-PrP was different. Challenge with ralpha-PrP elicited a strong response of IL-5 and IL-10, whereas rbeta-PrP led to an early increased production of IFN-gamma. In addition, immunization with ralpha-PrP led to production of predominantly IgG1 isotype Ab in the sera, whereas after immunization with rbeta-PrP, IgG2b was significantly produced. Thus, both humoral and cellular responses to these differently folded isoforms of the same protein are different, indicating a possible involvement of Th1 and Th2 pathway activation. These differences may be exploitable diagnostically and therapeutically for prion diseases, such as variant Creutzfeldt-Jakob disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15749856     DOI: 10.4049/jimmunol.174.6.3256

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice.

Authors:  Vivek S Purohit; C Russell Middaugh; Sathyamangalam V Balasubramanian
Journal:  J Pharm Sci       Date:  2006-02       Impact factor: 3.534

2.  Rational design of multiple TB antigens TB10.4 and TB10.4-Ag85B as subunit vaccine candidates against Mycobacterium tuberculosis.

Authors:  Shuai Shi; Lan Yu; Dengyun Sun; Jian Liu; Anthony J Hickey
Journal:  Pharm Res       Date:  2009-10-28       Impact factor: 4.200

3.  Characterization of conformation-dependent prion protein epitopes.

Authors:  Hae-Eun Kang; Chu Chun Weng; Eri Saijo; Vicki Saylor; Jifeng Bian; Sehun Kim; Laylaa Ramos; Rachel Angers; Katie Langenfeld; Vadim Khaychuk; Carla Calvi; Jason Bartz; Nora Hunter; Glenn C Telling
Journal:  J Biol Chem       Date:  2012-09-04       Impact factor: 5.157

4.  Ablation of the cellular prion protein, PrPC, specifically on follicular dendritic cells has no effect on their maturation or function.

Authors:  Laura McCulloch; Karen L Brown; Neil A Mabbott
Journal:  Immunology       Date:  2013-03       Impact factor: 7.397

5.  Conformation-dependent epitopes recognized by prion protein antibodies probed using mutational scanning and deep sequencing.

Authors:  Kyle M Doolan; David W Colby
Journal:  J Mol Biol       Date:  2014-11-07       Impact factor: 5.469

Review 6.  Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.

Authors:  Einar M Sigurdsson
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

Review 7.  Immunotherapy in prion disease.

Authors:  Yvonne Roettger; Yansheng Du; Michael Bacher; Inga Zerr; Richard Dodel; Jan-Philipp Bach
Journal:  Nat Rev Neurol       Date:  2012-12-18       Impact factor: 42.937

8.  A camelid anti-PrP antibody abrogates PrP replication in prion-permissive neuroblastoma cell lines.

Authors:  Daryl Rhys Jones; William Alexander Taylor; Clive Bate; Monique David; Mourad Tayebi
Journal:  PLoS One       Date:  2010-03-22       Impact factor: 3.240

9.  Influence of collagen-based integrin α1 and α2 mediated signaling on human mesenchymal stem cell osteogenesis in three dimensional contexts.

Authors:  Silvia M Becerra-Bayona; Viviana R Guiza-Arguello; Brooke Russell; Magnus Höök; Mariah S Hahn
Journal:  J Biomed Mater Res A       Date:  2018-09-08       Impact factor: 4.396

10.  Crystal structure of human prion protein bound to a therapeutic antibody.

Authors:  S V Antonyuk; C R Trevitt; R W Strange; G S Jackson; D Sangar; M Batchelor; S Cooper; C Fraser; S Jones; T Georgiou; A Khalili-Shirazi; A R Clarke; S S Hasnain; J Collinge
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.